The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
C Patel, JML Brotherton, A Pillsbury… - …, 2018 - eurosurveillance.org
Background: A National human papilloma virus (HPV) Vaccination Programme for the
prevention of HPV infection and associated disease using the quadrivalent HPV vaccine …
prevention of HPV infection and associated disease using the quadrivalent HPV vaccine …
An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015
M Vichnin, P Bonanni, NP Klein… - The Pediatric …, 2015 - journals.lww.com
Background: A quadrivalent human papillomavirus (HPV4) type 6/11/16/18 vaccine
(GARDASIL/SILGARD®) has been licensed in many countries around the world for the …
(GARDASIL/SILGARD®) has been licensed in many countries around the world for the …
Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation
D Saslow, KS Andrews… - CA: a cancer journal …, 2020 - Wiley Online Library
Abstract The American Cancer Society (ACS) presents an adaptation of the current Advisory
Committee on Immunization Practices recommendations for human papillomavirus (HPV) …
Committee on Immunization Practices recommendations for human papillomavirus (HPV) …
Long-term study of a quadrivalent human papillomavirus vaccine
D Ferris, R Samakoses, SL Block… - …, 2014 - publications.aap.org
BACKGROUND: We present a long-term safety, immunogenicity, and effectiveness study of
a quadrivalent human papillomavirus (HPV4) vaccine. METHODS: Sexually naive boys and …
a quadrivalent human papillomavirus (HPV4) vaccine. METHODS: Sexually naive boys and …
[HTML][HTML] Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: potential …
S Hartwig, JJ Baldauf, G Dominiak-Felden… - Papillomavirus …, 2015 - Elsevier
Introduction A second generation HPV vaccine has been developed for the prevention of
anogenital cancers and precancerous lesions of the cervix, vulva, vagina, anus and of …
anogenital cancers and precancerous lesions of the cervix, vulva, vagina, anus and of …
Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention
A Gradíssimo, RD Burk - Expert Review of Molecular Diagnostics, 2017 - Taylor & Francis
ABSTRACT Introduction: Human papillomavirus (HPV)-related cancers can be averted by
type-specific vaccination (primary prevention) and/or through detection and ablation of …
type-specific vaccination (primary prevention) and/or through detection and ablation of …
Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program …
Background. Human papillomavirus (HPV) vaccination targeting females aged 12–13 years
commenced in Australia in 2007, with catch-up vaccination of females aged 13–26 years …
commenced in Australia in 2007, with catch-up vaccination of females aged 13–26 years …
Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender-neutral vaccination …
Summary Background In Australia, the government-funded human papillomavirus (HPV)
vaccination programme was introduced in April, 2007, for girls and young women, and in …
vaccination programme was introduced in April, 2007, for girls and young women, and in …
The Australian experience with the human papillomavirus vaccine
SM Garland - Clinical therapeutics, 2014 - Elsevier
Objective The goal of this study was to review the current human papillomavirus (HPV)
vaccine program and its outcomes to date in Australia. Methods This was a review of the …
vaccine program and its outcomes to date in Australia. Methods This was a review of the …
Genital warts
M Steben, SM Garland - Best practice & research Clinical obstetrics & …, 2014 - Elsevier
Anogenital warts (AGWs) are a very common disease. They are caused mostly by low-risk
human papillomaviruses (HPV) 6 and 11, particularly the former. Clinical presentation is …
human papillomaviruses (HPV) 6 and 11, particularly the former. Clinical presentation is …